T1	Premise 1874 2024	Overall, the mean global QoL score improved during chemotherapy by 7·2 points (SD 24·4) when analysed for all women with data at baseline and week 18.
T2	Premise 2025 2227	The mean global QoL score at 54 weeks was higher in the standard chemotherapy group than in the bevacizumab group (76·1 [SD 18·2] vs 69·7 [19·1] points; difference 6·4 points, 95% CI 3·7-9·0, p<0·0001).
T3	Claim 2228 2406	Bevacizumab continuation treatment seems to be associated with a small but clinically significant decrement in QoL compared with standard treatment for women with ovarian cancer.
R1	Support Arg1:T2 Arg2:T3	
R2	Attack Arg1:T1 Arg2:T3	
